DelveInsight's, "Bladder Cancer Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Bladder cancer pipeline landscape. It covers the Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bladder Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Bladder Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Bladder Cancer Pipeline Outlook
Key Takeaways from the Bladder Cancer Pipeline Report*
Stay ahead with the most recent pipeline outlook for Bladder Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Bladder Cancer Treatment Drugs
Bladder cancer Emerging Drugs
UGN-102:
UGN-102 (mitomycin) for intravesical solution is an investigational drug formulation of mitomycin. It is been developed by utilizing UroGen's proprietary RTGel® technology which is a sustained release, hydrogel-based formulation, UGN-102 is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. UGN-102 is delivered to patients using a standard urinary catheter in an outpatient setting. Currently it is in Phase III stage of clinical trial for the treatment of Bladder Cancer.
APL 1202 :
APL-1202 is an orally available reversible MetAP2 Inhibitor with anti-angiogenic, anti-tumor activities and can also modulate tumor immune microenvironment. It is currently in registration clinical trials in
Trilaciclib:
Trilaciclib, is a first-in-class therapy designed to improve outcomes for people with cancer who are treated with chemotherapy. It is a transient IV-administered CDK4/6 inhibitor, a novel therapeutic approach which is given before chemotherapy that temporarily blocks progression through the cell cycle. Currently the drug is being evaluated in Phase II for the treatment of Bladder Cancer.
Catumaxomab:
Catumaxomab is a bispecific antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell--and CD3 on the T cell, recruits immune accessory cells through Fc?R binding at the same time. The drug kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. The drug is in Phase I/II stage of clinical trials for the treatment of bladder cancer.
VAX 014: Vaxiion Therapeutics
VAX014 is a novel rBMC-based oncolytic immunotherapy. VAX014is a first-in-class tumor-targeted oncolytic agent based on Vaxiion's proprietary rBMC technology. It works by specifically targeting and delivering a novel fast-acting pre-formed oncolytic protein toxin directly to tumor cells that express either ?3?1 or ?5?1 integrin(s), both commonly found to be selectively expressed in many solid tumor types. The drug is in Phase I stage of clinical trials for the treatment of bladder cancer.
Explore groundbreaking therapies and clinical trials in the Bladder Cancer Pipeline. Access DelveInsight's detailed report now! @ New Bladder Cancer Drugs
Bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration*
Bladder Cancer Products have been categorized under various Molecule types such as*Monoclonal Antibody *Peptides *Polymer *Small molecule *Gene therapy
Unveil the future of Bladder Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Bladder Cancer Market Drivers and Barriers
Scope of the Bladder Cancer Pipeline Report*Coverage- Global *Bladder Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination *Bladder Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III *
Get the latest on Bladder Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Bladder Cancer Companies, Key Products and Unmet Needs
Table of Content*Introduction *Executive Summary *Bladder Cancer : Overview *Pipeline Therapeutics *Therapeutic Assessment *Late Stage Products (Phase III) *UGN-102:
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company
Contact Person:
Email: ybhardwaj@delveinsight.com
Phone: +14699457679
Address:
City:
State:
Country:
Website: https://www.delveinsight.com/
Source: www.abnewswire.com
.
(C) 2024 M2 COMMUNICATIONS, source